MEthylene Blue In Patients With Acquired Methemoglobinemia

Summary

This is an open label, uncontrolled, Phase 4 study including 10 patients who present in hospital/urgent care setting with acquired methemoglobinemia. The population may include pediatric and adult patients (males and females of all ages are included). The study will run in both the EU and the US. The aim of the study is to confirm safety and efficacy of ProvayBlueTM for the treatment of acquired methemoglobinemia and has been requested by the US-FDA as a Post-Marketing requirements.

Timeline

Start

2018-07-06

Primary completion

2020-08-31

Completion

2020-08-31

Drugs

Indications